Oncolys BioPharma, Inc. (JP:4588) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Oncolys BioPharma Inc. reports a decrease in net sales by 50.2% and a significant operating loss for the first half of 2024 compared to the same period in 2023, with no dividends paid or forecasted. The company’s total assets decreased slightly, while the equity ratio increased to 74.7%. Oncolys has not provided a financial forecast for the end of the fiscal year, citing the difficulty of making reasonable estimates.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.